Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme

Showing 241 to 250 of 2003

TitleReference numberPublishedLast updated
Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancerDG58
Remdesivir and tixagevimab plus cilgavimab for treating COVID-19TA971
Selinexor with dexamethasone for treating relapsed and refractory multiple myeloma after 4 or more treatmentsTA970
Artificial intelligence (AI)-derived software to help clinical decision making in strokeDG57
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphomaTA540
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and overTA967
Gefapixant for treating refractory or unexplained chronic cough (terminated appraisal)TA969
Melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)TA968
Pembrolizumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer (terminated appraisal)TA966
Lymphovenous anastomosis during axillary or inguinal node dissection for preventing secondary lymphoedemaIPG785

Results per page

  1. 10
  2. 25
  3. 50
  4. All